FDA Approves Treatment of Chronic Hepatitis C Genotypes 1 and 4

February 1, 2016

Note: The following is an edited form of a press release from the Food and Drug Administration. The original form of the release can be read here. On Thursday, January 28, the U.S. Food and Drug Administration approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) […]

Sign up for E-mails, Dateline Newsletter, and other ways to stay connected.